Drug developers working in transplantation know the stakes. Preventing organ rejection remains one of the biggest challenges in modern medicine. Now, Eledon Pharmaceuticals has taken a step forward.
The company announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its investigational therapy tegoprubart for preventing allograft rejection in liver transplantation.
This designation strengthens the drug’s development pathway and highlights its potential in transplant medicine.
Tegoprubart is an investigational anti-CD40L antibody designed to regulate immune responses involved in organ rejection.
Unlike traditional immunosuppressants, the therapy targets CD40 Ligand signaling, a key pathway involved in immune cell activation.
By blocking this pathway, tegoprubart aims to:
These benefits could make it a valuable alternative to calcineurin inhibitors, which remain widely used but often cause significant complications.
Early clinical research in kidney transplantation has already shown encouraging results.
According to David-Alexandre C. Gros, CEO of Eledon Pharmaceuticals:
These findings have encouraged the company to expand development into liver transplantation.
An investigator-sponsored clinical trial evaluating tegoprubart in liver transplant patients is expected to begin later this year.
The liver transplant designation adds to a growing list of regulatory recognitions for tegoprubart.
The therapy has already received orphan drug status from the U.S. Food and Drug Administration for:
This expanding regulatory support reflects the drug’s broad therapeutic potential in immune-mediated diseases.
Orphan Drug Designation is designed to encourage treatments for rare conditions. In the United States, a disease is considered rare if it affects fewer than 200,000 people.
The designation provides developers with several incentives, including:
These benefits help accelerate the development of therapies targeting serious conditions with limited treatment options.
Eledon Pharmaceuticals is focused on immune-modulating therapies for life-threatening diseases.
Its lead candidate, tegoprubart, is currently being explored across multiple indications, including:
By targeting CD40 Ligand biology, the company aims to develop non-lymphocyte-depleting immunotherapies that offer better safety and long-term outcomes.
The new orphan drug designation marks another milestone for tegoprubart’s development.
If clinical studies confirm its early promise, the therapy could reshape how transplant rejection is managed.
For patients awaiting life-saving organ transplants, that possibility could make a significant difference.